Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.41 |
| ▸ | IDH2 | P48735 | 5/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.41 |
| ▸ | AKT1 | P31749 | 2/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19689772 | 0.88 | CNR2 (0.43) | KDM1AIDH2KMONOTUMCNR2 | |
| SCHEMBL19689787 | 0.87 | KDM1A (0.43) | KDM1AIDH2RPS6KB1KMONOTUM | |
| SCHEMBL17778800 | 0.86 | CSNK1E (0.41) | KDM1AIDH2KMONOTUMCNR2 | |
| SCHEMBL16238287 | 0.86 | IDH2 (0.40) | KDM1AIDH2KMONOTUM | |
| SCHEMBL16238289 | 0.86 | IDH2 (0.40) | KDM1AIDH2KMONOTUM | |
| SCHEMBL17618783 | 0.86 | MEN1 (0.47) | IDH2MEN1ALDH1A1KMT2A | |
| SCHEMBL17618807 | 0.85 | PLG (0.44) | IDH2RPS6KB1AKT1JAK2MEN1 | |
| SCHEMBL19699711 | 0.85 | ALDH1A1 (0.44) | KDM1AIDH2RPS6KB1MAOAMAOB | |
| SCHEMBL17618383 | 0.85 | CNR2 (0.41) | KDM1AIDH2CNR2MEN1ALDH1A1 | |
| SCHEMBL19689810 | 0.85 | ALDH1A1 (0.42) | KDM1AIDH2RPS6KB1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355705-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | KDM1A 903/4885IDH2 34/4885RPS6KB1 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.